Lucid Diagnostics price target raised to $7.50 from $7 at Ascendiant

Ascendiant raised the firm’s price target on Lucid Diagnostics (LUCD) to $7.50 from $7 and keeps a Buy rating on the shares following the Q4 report. Lucid’s devices still have long commercialization and growth challenges ahead, but the “billion dollars market potential presents high rewards for the risks,” the analyst tells investors in a research note. The firm says the company’s expected high growth in 2025 should drive the stock “much higher.”